Compile Data Set for Download or QSAR
Found 47 Enz. Inhib. hit(s) with all data for entry = 50037191
TargetProtein kinase C beta type(Homo sapiens (Human))
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50133057(17,20,23-trioxa-4,14,26-triazahexacyclo[24.6.1.17,...)copy SMILEScopy InChI
Affinity DataIC50: 6nMAssay Description:Inhibition of Protein kinase C beta 2More data for this Ligand-Target Pair
In DepthDetails Article
BindingDB Entry DOI: 10.7270/Q2G44R1DPubMed
TargetProtein kinase C beta type(Homo sapiens (Human))
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM17055((18S)-18-[(dimethylamino)methyl]-17-oxa-4,14,21-tr...)copy SMILEScopy InChI
Affinity DataIC50: 6nMAssay Description:Inhibition of Protein kinase C beta 2More data for this Ligand-Target Pair
In DepthDetails Article
BindingDB Entry DOI: 10.7270/Q2G44R1DPubMed
TargetGlycogen synthase kinase-3 beta(Homo sapiens (Human))
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50133059(17,20,23-trioxa-4,12,14,26-tetraazahexacyclo[24.6....)copy SMILEScopy InChI
Affinity DataIC50: 17nMAssay Description:Inhibition of Glycogen synthase kinase-3beta (GSK3-beta)More data for this Ligand-Target Pair
In DepthDetails Article
BindingDB Entry DOI: 10.7270/Q2G44R1DPubMed
TargetGlycogen synthase kinase-3 beta(Homo sapiens (Human))
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50133061(17,20,23,26-tetraoxa-4,14,29-triazahexacyclo[27.6....)copy SMILEScopy InChI
Affinity DataIC50: 26nMAssay Description:Inhibition of Glycogen synthase kinase-3beta (GSK3-beta)More data for this Ligand-Target Pair
In DepthDetails Article
BindingDB Entry DOI: 10.7270/Q2G44R1DPubMed
TargetGlycogen synthase kinase-3 beta(Homo sapiens (Human))
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50133064(17,20,23-trioxa-4,12,14,26,28-pentaazahexacyclo[24...)copy SMILEScopy InChI
Affinity DataIC50: 34nMAssay Description:Inhibition of Glycogen synthase kinase-3beta (GSK3-beta)More data for this Ligand-Target Pair
In DepthDetails Article
BindingDB Entry DOI: 10.7270/Q2G44R1DPubMed
TargetProtein kinase C beta type(Homo sapiens (Human))
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50133059(17,20,23-trioxa-4,12,14,26-tetraazahexacyclo[24.6....)copy SMILEScopy InChI
Affinity DataIC50: 46nMAssay Description:Inhibition of Protein kinase C beta 2More data for this Ligand-Target Pair
In DepthDetails Article
BindingDB Entry DOI: 10.7270/Q2G44R1DPubMed
TargetGlycogen synthase kinase-3 beta(Homo sapiens (Human))
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50133058(17,20,23,26-tetraoxa-4,12,14,29,31-pentaazahexacyc...)copy SMILEScopy InChI
Affinity DataIC50: 48nMAssay Description:Inhibition of Glycogen synthase kinase-3beta (GSK3-beta)More data for this Ligand-Target Pair
In DepthDetails Article
BindingDB Entry DOI: 10.7270/Q2G44R1DPubMed
TargetGlycogen synthase kinase-3 beta(Homo sapiens (Human))
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50133065(17,20,23,26,29-pentaoxa-4,14,32-triazahexacyclo[30...)copy SMILEScopy InChI
Affinity DataIC50: 51nMAssay Description:Inhibition of Glycogen synthase kinase-3beta (GSK3-beta)More data for this Ligand-Target Pair
In DepthDetails Article
BindingDB Entry DOI: 10.7270/Q2G44R1DPubMed
TargetProtein kinase C theta type(Homo sapiens (Human))
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50133057(17,20,23-trioxa-4,14,26-triazahexacyclo[24.6.1.17,...)copy SMILEScopy InChI
Affinity DataIC50: 65nMAssay Description:Inhibition of Protein kinase C thetaMore data for this Ligand-Target Pair
In DepthDetails Article
BindingDB Entry DOI: 10.7270/Q2G44R1DPubMed
TargetProtein kinase C alpha type(Homo sapiens (Human))
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50133057(17,20,23-trioxa-4,14,26-triazahexacyclo[24.6.1.17,...)copy SMILEScopy InChI
Affinity DataIC50: 86nMAssay Description:Inhibition of Protein kinase C alphaMore data for this Ligand-Target Pair
In DepthDetails Article
BindingDB Entry DOI: 10.7270/Q2G44R1DPubMed
TargetGlycogen synthase kinase-3 beta(Homo sapiens (Human))
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50133063(17,20-dioxa-4,14,23-triazahexacyclo[21.6.1.17,14.0...)copy SMILEScopy InChI
Affinity DataIC50: 136nMAssay Description:Inhibition of Glycogen synthase kinase-3beta (GSK3-beta)More data for this Ligand-Target Pair
In DepthDetails Article
BindingDB Entry DOI: 10.7270/Q2G44R1DPubMed
TargetGlycogen synthase kinase-3 beta(Homo sapiens (Human))
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50133067(17,20-dioxa-4,12,14,23-tetraazahexacyclo[21.6.1.17...)copy SMILEScopy InChI
Affinity DataIC50: 138nMAssay Description:Inhibition of Glycogen synthase kinase-3beta (GSK3-beta)More data for this Ligand-Target Pair
In DepthDetails Article
BindingDB Entry DOI: 10.7270/Q2G44R1DPubMed
TargetGlycogen synthase kinase-3 beta(Homo sapiens (Human))
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50133057(17,20,23-trioxa-4,14,26-triazahexacyclo[24.6.1.17,...)copy SMILEScopy InChI
Affinity DataIC50: 220nMAssay Description:Inhibition of Glycogen synthase kinase-3beta (GSK3-beta)More data for this Ligand-Target Pair
In DepthDetails Article
BindingDB Entry DOI: 10.7270/Q2G44R1DPubMed
TargetProtein kinase C gamma type(Homo sapiens (Human))
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM17055((18S)-18-[(dimethylamino)methyl]-17-oxa-4,14,21-tr...)copy SMILEScopy InChI
Affinity DataIC50: 300nMAssay Description:Inhibition of Protein kinase C gamma (PKC-gamma)More data for this Ligand-Target Pair
In DepthDetails Article
BindingDB Entry DOI: 10.7270/Q2G44R1DPubMed
TargetProtein kinase C alpha type(Homo sapiens (Human))
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM17055((18S)-18-[(dimethylamino)methyl]-17-oxa-4,14,21-tr...)copy SMILEScopy InChI
Affinity DataIC50: 360nMAssay Description:Inhibition of Protein kinase C alphaMore data for this Ligand-Target Pair
In DepthDetails Article
BindingDB Entry DOI: 10.7270/Q2G44R1DPubMed
TargetGlycogen synthase kinase-3 beta(Homo sapiens (Human))
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50133060(17,20,23,26,29-pentaoxa-4,12,14,32,34-pentaazahexa...)copy SMILEScopy InChI
Affinity DataIC50: 403nMAssay Description:Inhibition of Glycogen synthase kinase-3beta (GSK3-beta)More data for this Ligand-Target Pair
In DepthDetails Article
BindingDB Entry DOI: 10.7270/Q2G44R1DPubMed
TargetGlycogen synthase kinase-3 beta(Homo sapiens (Human))
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50133066(17,20-dioxa-4,12,14,23,25-pentaazahexacyclo[21.6.1...)copy SMILEScopy InChI
Affinity DataIC50: 620nMAssay Description:Inhibition of Glycogen synthase kinase-3beta (GSK3-beta)More data for this Ligand-Target Pair
In DepthDetails Article
BindingDB Entry DOI: 10.7270/Q2G44R1DPubMed
TargetProtein kinase C alpha type(Homo sapiens (Human))
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50133059(17,20,23-trioxa-4,12,14,26-tetraazahexacyclo[24.6....)copy SMILEScopy InChI
Affinity DataIC50: 673nMAssay Description:Inhibition of Protein kinase C alphaMore data for this Ligand-Target Pair
In DepthDetails Article
BindingDB Entry DOI: 10.7270/Q2G44R1DPubMed
TargetProtein kinase C theta type(Homo sapiens (Human))
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50133059(17,20,23-trioxa-4,12,14,26-tetraazahexacyclo[24.6....)copy SMILEScopy InChI
Affinity DataIC50: 835nMAssay Description:Inhibition of Protein kinase C thetaMore data for this Ligand-Target Pair
In DepthDetails Article
BindingDB Entry DOI: 10.7270/Q2G44R1DPubMed
TargetCyclin-dependent kinase 2(Homo sapiens (Human))
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50133057(17,20,23-trioxa-4,14,26-triazahexacyclo[24.6.1.17,...)copy SMILEScopy InChI
Affinity DataIC50: 992nMAssay Description:Inhibition of Cyclin-dependent kinase 2 (CDK2)More data for this Ligand-Target Pair
In DepthDetails Article
BindingDB Entry DOI: 10.7270/Q2G44R1DPubMed
TargetProtein kinase C beta type(Homo sapiens (Human))
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50133064(17,20,23-trioxa-4,12,14,26,28-pentaazahexacyclo[24...)copy SMILEScopy InChI
Affinity DataIC50: 1.16E+3nMAssay Description:Inhibition of Protein kinase C beta 2More data for this Ligand-Target Pair
In DepthDetails Article
BindingDB Entry DOI: 10.7270/Q2G44R1DPubMed
TargetProtein kinase C gamma type(Homo sapiens (Human))
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50133057(17,20,23-trioxa-4,14,26-triazahexacyclo[24.6.1.17,...)copy SMILEScopy InChI
Affinity DataIC50: 1.20E+3nMAssay Description:Inhibition of Protein kinase C gamma (PKC-gamma)More data for this Ligand-Target Pair
In DepthDetails Article
BindingDB Entry DOI: 10.7270/Q2G44R1DPubMed
TargetCyclin-dependent kinase 1(Homo sapiens (Human))
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50133057(17,20,23-trioxa-4,14,26-triazahexacyclo[24.6.1.17,...)copy SMILEScopy InChI
Affinity DataIC50: 1.25E+3nMAssay Description:Inhibition of Cyclin-dependent kinase 1More data for this Ligand-Target Pair
In DepthDetails Article
BindingDB Entry DOI: 10.7270/Q2G44R1DPubMed
TargetProtein kinase C gamma type(Homo sapiens (Human))
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50133059(17,20,23-trioxa-4,12,14,26-tetraazahexacyclo[24.6....)copy SMILEScopy InChI
Affinity DataIC50: 1.34E+3nMAssay Description:Inhibition of Protein kinase C gamma (PKC-gamma)More data for this Ligand-Target Pair
In DepthDetails Article
BindingDB Entry DOI: 10.7270/Q2G44R1DPubMed
TargetCyclin-dependent kinase 2(Homo sapiens (Human))
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50133059(17,20,23-trioxa-4,12,14,26-tetraazahexacyclo[24.6....)copy SMILEScopy InChI
Affinity DataIC50: 2.44E+3nMAssay Description:Inhibition of Cyclin-dependent kinase 2 (CDK2)More data for this Ligand-Target Pair
In DepthDetails Article
BindingDB Entry DOI: 10.7270/Q2G44R1DPubMed
TargetProtein kinase C gamma type(Homo sapiens (Human))
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50133067(17,20-dioxa-4,12,14,23-tetraazahexacyclo[21.6.1.17...)copy SMILEScopy InChI
Affinity DataIC50: 2.67E+3nMAssay Description:Inhibition of Protein kinase C gamma (PKC-gamma)More data for this Ligand-Target Pair
In DepthDetails Article
BindingDB Entry DOI: 10.7270/Q2G44R1DPubMed
TargetProtein kinase C gamma type(Homo sapiens (Human))
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50133063(17,20-dioxa-4,14,23-triazahexacyclo[21.6.1.17,14.0...)copy SMILEScopy InChI
Affinity DataIC50: 2.73E+3nMAssay Description:Inhibition of Protein kinase C gamma (PKC-gamma)More data for this Ligand-Target Pair
In DepthDetails Article
BindingDB Entry DOI: 10.7270/Q2G44R1DPubMed
TargetProtein kinase C gamma type(Homo sapiens (Human))
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50133061(17,20,23,26-tetraoxa-4,14,29-triazahexacyclo[27.6....)copy SMILEScopy InChI
Affinity DataIC50: 3.30E+3nMAssay Description:Inhibition of Protein kinase C gamma (PKC-gamma)More data for this Ligand-Target Pair
In DepthDetails Article
BindingDB Entry DOI: 10.7270/Q2G44R1DPubMed
TargetCyclin-dependent kinase 1(Homo sapiens (Human))
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50133059(17,20,23-trioxa-4,12,14,26-tetraazahexacyclo[24.6....)copy SMILEScopy InChI
Affinity DataIC50: 4.43E+3nMAssay Description:Inhibition of Cyclin-dependent kinase 1More data for this Ligand-Target Pair
In DepthDetails Article
BindingDB Entry DOI: 10.7270/Q2G44R1DPubMed
TargetProtein kinase C gamma type(Homo sapiens (Human))
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50133065(17,20,23,26,29-pentaoxa-4,14,32-triazahexacyclo[30...)copy SMILEScopy InChI
Affinity DataIC50: 5.17E+3nMAssay Description:Inhibition of Protein kinase C gamma (PKC-gamma)More data for this Ligand-Target Pair
In DepthDetails Article
BindingDB Entry DOI: 10.7270/Q2G44R1DPubMed
TargetCalcium/calmodulin-dependent protein kinase type II subunit alpha/beta/delta/gamma(Homo sapiens (Human))
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50133059(17,20,23-trioxa-4,12,14,26-tetraazahexacyclo[24.6....)copy SMILEScopy InChI
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of Calcium/calmodulin-dependent protein kinase IIMore data for this Ligand-Target Pair
In DepthDetails Article
BindingDB Entry DOI: 10.7270/Q2G44R1DPubMed
TargetCalcium/calmodulin-dependent protein kinase type II subunit alpha/beta/delta/gamma(Homo sapiens (Human))
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50133057(17,20,23-trioxa-4,14,26-triazahexacyclo[24.6.1.17,...)copy SMILEScopy InChI
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of Calcium/calmodulin-dependent protein kinase IIMore data for this Ligand-Target Pair
In DepthDetails Article
BindingDB Entry DOI: 10.7270/Q2G44R1DPubMed
TargetCalcium/calmodulin-dependent protein kinase type II subunit alpha/beta/delta/gamma(Homo sapiens (Human))
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50133064(17,20,23-trioxa-4,12,14,26,28-pentaazahexacyclo[24...)copy SMILEScopy InChI
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of Calcium/calmodulin-dependent protein kinase IIMore data for this Ligand-Target Pair
In DepthDetails Article
BindingDB Entry DOI: 10.7270/Q2G44R1DPubMed
TargetProtein kinase C gamma type(Homo sapiens (Human))
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50133066(17,20-dioxa-4,12,14,23,25-pentaazahexacyclo[21.6.1...)copy SMILEScopy InChI
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of Protein kinase C gamma (PKC-gamma)More data for this Ligand-Target Pair
In DepthDetails Article
BindingDB Entry DOI: 10.7270/Q2G44R1DPubMed
TargetProtein kinase C beta type(Homo sapiens (Human))
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50133058(17,20,23,26-tetraoxa-4,12,14,29,31-pentaazahexacyc...)copy SMILEScopy InChI
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of Protein kinase C beta 2More data for this Ligand-Target Pair
In DepthDetails Article
BindingDB Entry DOI: 10.7270/Q2G44R1DPubMed
TargetCalcium/calmodulin-dependent protein kinase type II subunit alpha/beta/delta/gamma(Homo sapiens (Human))
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50133058(17,20,23,26-tetraoxa-4,12,14,29,31-pentaazahexacyc...)copy SMILEScopy InChI
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of Calcium/calmodulin-dependent protein kinase IIMore data for this Ligand-Target Pair
In DepthDetails Article
BindingDB Entry DOI: 10.7270/Q2G44R1DPubMed
TargetProtein kinase C alpha type(Homo sapiens (Human))
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50133064(17,20,23-trioxa-4,12,14,26,28-pentaazahexacyclo[24...)copy SMILEScopy InChI
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of Protein kinase C alphaMore data for this Ligand-Target Pair
In DepthDetails Article
BindingDB Entry DOI: 10.7270/Q2G44R1DPubMed
TargetCyclin-dependent kinase 1(Homo sapiens (Human))
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50133064(17,20,23-trioxa-4,12,14,26,28-pentaazahexacyclo[24...)copy SMILEScopy InChI
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of Cyclin-dependent kinase 1More data for this Ligand-Target Pair
In DepthDetails Article
BindingDB Entry DOI: 10.7270/Q2G44R1DPubMed
TargetProtein kinase C gamma type(Homo sapiens (Human))
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50133058(17,20,23,26-tetraoxa-4,12,14,29,31-pentaazahexacyc...)copy SMILEScopy InChI
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of Protein kinase C gamma (PKC-gamma)More data for this Ligand-Target Pair
In DepthDetails Article
BindingDB Entry DOI: 10.7270/Q2G44R1DPubMed
TargetCyclin-dependent kinase 2(Homo sapiens (Human))
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50133064(17,20,23-trioxa-4,12,14,26,28-pentaazahexacyclo[24...)copy SMILEScopy InChI
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of Cyclin-dependent kinase 2 (CDK2)More data for this Ligand-Target Pair
In DepthDetails Article
BindingDB Entry DOI: 10.7270/Q2G44R1DPubMed
TargetProtein kinase C theta type(Homo sapiens (Human))
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50133064(17,20,23-trioxa-4,12,14,26,28-pentaazahexacyclo[24...)copy SMILEScopy InChI
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of Protein kinase C thetaMore data for this Ligand-Target Pair
In DepthDetails Article
BindingDB Entry DOI: 10.7270/Q2G44R1DPubMed
TargetProtein kinase C alpha type(Homo sapiens (Human))
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50133058(17,20,23,26-tetraoxa-4,12,14,29,31-pentaazahexacyc...)copy SMILEScopy InChI
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of Protein kinase C alphaMore data for this Ligand-Target Pair
In DepthDetails Article
BindingDB Entry DOI: 10.7270/Q2G44R1DPubMed
TargetProtein kinase C gamma type(Homo sapiens (Human))
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50133064(17,20,23-trioxa-4,12,14,26,28-pentaazahexacyclo[24...)copy SMILEScopy InChI
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of Protein kinase C gamma (PKC-gamma)More data for this Ligand-Target Pair
In DepthDetails Article
BindingDB Entry DOI: 10.7270/Q2G44R1DPubMed
TargetCyclin-dependent kinase 1(Homo sapiens (Human))
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50133058(17,20,23,26-tetraoxa-4,12,14,29,31-pentaazahexacyc...)copy SMILEScopy InChI
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of Cyclin-dependent kinase 1More data for this Ligand-Target Pair
In DepthDetails Article
BindingDB Entry DOI: 10.7270/Q2G44R1DPubMed
TargetCyclin-dependent kinase 2(Homo sapiens (Human))
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50133058(17,20,23,26-tetraoxa-4,12,14,29,31-pentaazahexacyc...)copy SMILEScopy InChI
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of Cyclin-dependent kinase 2 (CDK2)More data for this Ligand-Target Pair
In DepthDetails Article
BindingDB Entry DOI: 10.7270/Q2G44R1DPubMed
TargetProtein kinase C gamma type(Homo sapiens (Human))
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50133060(17,20,23,26,29-pentaoxa-4,12,14,32,34-pentaazahexa...)copy SMILEScopy InChI
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of Protein kinase C gamma (PKC-gamma)More data for this Ligand-Target Pair
In DepthDetails Article
BindingDB Entry DOI: 10.7270/Q2G44R1DPubMed
TargetProtein kinase C theta type(Homo sapiens (Human))
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50133058(17,20,23,26-tetraoxa-4,12,14,29,31-pentaazahexacyc...)copy SMILEScopy InChI
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of Protein kinase C thetaMore data for this Ligand-Target Pair
In DepthDetails Article
BindingDB Entry DOI: 10.7270/Q2G44R1DPubMed